Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancerDomenico Albino, Giuseppina M. Carbone, Giada Sandrini et al.|Communications Biology|2021Cited by 44
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.Vincenzo Gennusa, Edoardo Francini, Calogero Saieva et al.|Journal of Clinical Oncology|2023Cited by 1